Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients

American Journal of Respiratory and Critical Care Medicine

Volumn 155, Issue 4, 1997, Pages 1469-1473

  Parsons, Polly E ^a   Moss, Marc ^b   Vannice, James L ^b   Moore, Ernest E ^b   Moore, Frederick A ^b   Repine, John E ^b  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DEVELOPMENT; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SURVIVAL;

EID: 0030970812     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.155.4.9105096     Document Type: Article

References (34)

1. Okusawa, S., J. A. Gelfand, T. Ikejima, R. J. Connolly, and C. A. Dinarello. 1988. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J.Clin. Invest. 81:1162-1172.
2. Fischer, E., M. A. Marano, A. E. Barber, A. Hudson, K. Lee, C. S. Rock, A. S. Hawes, R. C. Thompson, T. J. Hayes, T. D. Anderson, W. R. Benjamin, S. F. Lowry, and L. L. Moldawar. 1991. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am. Physiol. 261:R442-R452.
3. Leff, J. A., J. W. Baer, M. E. Bodman, J. M. Kirkman, P. F. Shanley, L. M. Patton, D. M. Guidot, C. J. Beehler, J. M. McCord, and J. E. Repine. 1994. Interleukin-1 alpha-induced lung neutrophil accumulation and oxygen metabolite mediated lung leak in rats. J. Appl. Physiol. 266:2-8.
4. Granowiz, E. V., A. A. Santos, D. D. Poutsiaka, D. W. Cannon, S. M. Wolff and C. A. Dinarello. 1991. Production of interleukin-1-receptor antagonist during experimental endoxaemia. Lancet 338:1423-1424.
5. Siler, T. N., J. E. Swierkosz, T. M. Hyers, A. A. Fowler, and R. O. Webster. 1989. Immunoreactive interleukin-1 in bronchoalveolar lavage fluid of high risk patients and patients with ARDS. Exp. Lung Res. 15:881-894.
6. Kunkel, A. L., T. Standiford, K. Kasahare, and R. M. Strieter. 1991. Interleukin-8: the major neutrophil chemotactic factor in the lung. Exp. Lung Res. 17:17-23.
7. Van Zee, K. J., L. E. DeForge, E. Fishcher, M. A. Marano, J. S. Kenney, D. G. Remick, S. F. Lowry, and L. I. Moldawer. 1991. IL-8 in septic shock, endotoxemia, and after IL-1 administration. J. Immunol. 146:3478-3482.
8. Donnelly, S. C., R. M. Strieter, S. L. Kunkel, A. Walx, C. R. Robertson, D. C. Carter, I. D. Grant, A. J. Pollok, and C. Halsett. 1993. Interleukin-8 and the development of adult respiratory distress syndrome in at-risk patient groups. Lancet 341:643-647.
9. Tracey, K. J., S. F. Lowry, and A. Cerami. 1988. Cachectin/TNF-α in septic shock and septic adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138:1377-1379.
10. Parsons, P. E., F. A. Moore, E. E. Moore, D. N. Ikle, P. M. Henson, and G. S. Worthen. 1992. Studies on the role of tumor necrosis factor in adult respiratory distress syndrome. Am. Rev. Respir. Dis. 146:694-700.
11. Marks, J. D., C. B. Marks, J. M. Luce, A. B. Montgomery, J. Turner, C. A. Metz, and J. F. Murray. 1990. Plasma tumor necrosis factor in patients with septic shock. Am. Rev. Respir. Dis. 141:94-97.
12. Dinarello, C. A. 1991 Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652.
13. Fischer, E., M. Marano, K. J. Van Zee, C. S. Roc, A. S. Hawes, W. A. Thompson, L. DeForge, J. S. Kenney, D. G. Remick, D. C. Bloedow, R. C. Thompson, S. F. Lowry, and L. L. Moldawer. 1991. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest. 89:1551-1557.
14. Rose, C. E., C. A. Juliano, D. T. Tracey, T. Yoshimurs, and A. M. Fu. 1994. Role of interleukin-1 in endotoxin-induced lung injury in the rat. Am. J. Respir. Cell Mol. Biol. 10:214-221.
15. Wakabayaski, G. O., J. A. Gelfand, J. F. Burke, R. C. Thompson, and C. A. Dinarello. 1991. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 5:338-343.
16. Leff, J. A., M. E. Bodman, O. J. Cho, S. Rohrback, O. K. Reiss, J. L. Vannice, and J. E. Repine. 1994. Post-insult treatment with interleukin-1 receptor antagonist decreased oxidative lung injury in rats given intrachael interleukin-1. Am. J. Respir. Crit. Care Med. 150:109-112.
17. Fischer, E., K. J. Van Zee, M. A. Marano, C. S. Rock, J. S. Kenney, D. D. Poutisiaka, C. A. Dinarello, S. F. Lowry, and L. L. Moldawer. 1992. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79:2196-2199.
18. Mandrup-Paulsen, T., L. D. Wogensen, M. Jensen, P. Svensson, P. Nilsson, T. Emdal, J. Molvig, C. A. Dinarello, J. Nerup, and J. Melvig. 1995. Circulating interleukin receptor antagonist concentrations are increased in adult patients with thermal injury. Crit. Care Med. 3:26-33.
19. de Waal Malefyt, R. J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209-1220.
20. Fiorentine, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. Ogarra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-3822.
21. Wang, P., P. Wu, J. C. Anthes, M. K. Siegel, R. W. Egan and M. M. Billah. 1994. Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 83:2678-2683.
22. Cassatella, M. A., L. Meda, S. Gasperini, F. Calzetti, and S. Bonora. 1994. Interleukin-10 (IL-10) upregulated IL-1 receptor antagonist production from lipopolysaccharide stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J. Exp. Med. 179:1695-1699.
23. Marchant, A., C. Bruyns, P. Vandenabeele, M. Ducarme, C. Gerard, A. Delvaux, D. DeGroote, D. Abramowicz, T. Velu, and M. Goldman. 1994. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 24:1167-1171.
24. Gerard, C., C. Bruyns, A. Marchant, D. Abramowicz, P. Vandenabeele, A. Delvaux, W. Fiers, M. Goldman, and T. Belu. 1993. Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:1205-1208.
25. Marchant, A., J. Deviere, B. Byl, D. DeGroote, J. Vincent, and M. Goldman. 1994. Interleukin-10 production during septicaemia. Lancet 343:707-708.
26. Hart, P. H., G. F. Vitti, D. R. Burgess, G. A. Whitty, D. S. Piccoli, and J. A. Hamilton. 1989. Potential anti-inflammatory effects of interleukin-4: suppression of human monocyte tumor necrosis factor alpha, interleukin-1 and prostaglandin E2. Proc. Natl. Acad. Sci. U.S.A. 86:3803-3807.
27. Vannier, E., L. C. Miller, and C. A. Dinarello. 1992. Coordinated anti-inflammatory effects of interleukin 4: IL-4 suppresses IL-1 production but upregulates gene expression and synthesis of interleukin-1 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 89:4076-4080.
28. Berg, D. J., M. W. Leach, M. R. Kuhn, K. Rajewsky, W. Muller, N. J. Davidson, and D. Rennick. 1995. Interleukin-10 but not interleukin-4 is a natural suppressant of cutaneous inflammatory responses. J. Exp. Med. 182:99-108.
29. Dechanet, J., M.-C. Rissoan, J. Bancherrau, and P. Miossec. 1995. Interleukin-4, but not interleukin-10, regulates the production of inflammation mediators by rheumatoid synoviocytes. Cytokine 7:176-183.
30. Moss, M., L. Ackerson, M. K. Gillespie, P. A. Moore, E. E. Moore, and P. E. Parsons. 1995. Von Willebrand factor antigen levels are not predictive for the adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 151:15-20.
31. Fowler, A. A., R. F. Hammon, J. T. Good, K. N. Benson, M. Baird, D. J. Eberle, T. L. Petty, and R. M. Hyers. 1983. Adult respiratory distress syndrome: risk with common predispositions. Ann. Intern. Med. 98:593-597.
32. Pepe, P. E., R. T. Potkin, D. H. Reus, L. D. Hudson, and C. J. Carrico. 1983. Clinical predictors of the adult respiratory distress syndrome. Am. J. Surg. 144:124-128.
33. Abraham, E., R. Wunderink, H. Silverman, T. M. Perl, S. Nasraway, H. Levy, R. Bone, R. P. Wenzel, P. Balk, R. Allred, J. E. Pennington, and J. C. Wherry. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. J.A.M.A. 273:934-941.
34. Fisher, C. J., J.-F. A. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, H. D. Reines, M. P. Shelly, B. W. Thompson, J. F. LaBrecque, M. A. Catalano, W. A. Knaus, and J. C. Sadoff. 1994. Recombinant human interleukin-1 receptor antagonist in the treatment of sepsis syndrome: results from a randomized, double-blind, placebo-controlled multicenter trial. J.A.M.A. 271:1836-1843.